Status:
UNKNOWN
Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer
Lead Sponsor:
Aarhus University Hospital
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Patients undergoing lung resection due to pulmonary cancer can be compromised in their postoperative period due to atrial fibrillation. A retrospective analysis performed at our institution indicates...
Eligibility Criteria
Inclusion
- Resection of the lung due to confirmed diagnosis of cancer pulmones.
- Elective operation (scheduled operation for at least one day)
- Ready to be randomized
- Patient must be at least 18 at time of operation
Exclusion
- Former operation of the lung
- Former heart surgery
- Bradycardia below 40 beats/ min
- Hypotension with systolic blood pressure below 80 mmHg
- AV-blockage of any degree or sick sinus node
- QTc interval above 440 ms for men or above 460 ms for women
- Paroxysmal, persistent or permanent atrial fibrillation or flutter
- Former atrial fibrillation or flutter for more than a month.
- Pregnant or positive pregnancy test
- Breastfeeding
- ALAT of more than twice the normal over limit
- Treatment with monoamineoxidase inhibitors (MAOI)
- Allergy to one or more components in amiodarone
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2009
Estimated Enrollment :
275 Patients enrolled
Trial Details
Trial ID
NCT00724581
Start Date
August 1 2008
End Date
December 1 2009
Last Update
July 29 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aarhus University Hospital, Skejby
Aarhus, Denmark, DK-8200